Glycemic Response to Oral Nutrition Supplements

Nestlé

Status: Completed

Conditions: Diabetes

Treatments: Other: ONS

Study type: Interventional

Funder types: Industry

Identifiers

NCT02612675

13.10.US.HCN

Details and patient eligibility

About

This will be a randomized, cross-over study of two oral nutrition supplements in individuals with Type 2 Diabetes.

Enrollment: 13 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 20-75 yrs
• Type 2 diabetes controlled with diet or diet and oral agent, with the exception of sulfonylureas such as glimepiride (Amaryl), glipizide (Glucotrol/Glucotrol XL) and glyburide (DiaBeta, Micronase, Glynase Prestabs); meglitinides such as reaglinide (Prandin) and nateglinide (Starlix); and alpha-glucosidase inhibitors such as acarbose (Precose) and miglitol (Glyset)
• Hemoglobin A1C less than 9.0%
• Fasting blood glucose less than 180 mg

Exclusion criteria

• Allergy to milk protein or any other component of the formula

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

13 participants in 2 patient groups

Standard ONS

Active Comparator group

Description:

Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption

Treatment:

Other: ONS

Low Carbohydrate ONS

Experimental group

Description:

Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption

Treatment:

Other: ONS